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ABSTRACT 
 
The nitrile imines generated by the oxidative dehydrogenation of aldehyde phenylhydrazones with chloramine-T in 
ethyl alcohol undergo 1,3-dipolar cycloaddition with benzalacetone in situ to afford 1-(3-aryl-1,4-diphenyl-4,5-
dihydro-1H-pyrazol-5-yl)ethanones in good yield. The structure proofs of the synthesized new cycloadducts were 
provided by IR, 1H NMR, 13C NMR, Mass spectral studies and elemental analysis. The new compounds were 
evaluated in vitro for their antimicrobial and antioxidant activities.   
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INTRODUCTION 
 
The five membered heterocycles such as pyrazoles and their analogs are interesting class compounds in 
pharmaceutical and medicinal chemistry. They were considered as useful synthons in organic synthesis in 
constructing biologically active molecules. The pyrazoles acts as selective inhibitors of tissue-nonspecific alkaline 
phosphatase [1]. They were known to exhibit antitubercular [2], antiviral [3], antimicrobial [4], antioxidant [5], 
antitumor and antiangiogenic properties [6].  
 
A series of structurally related 1H-pyrazolyl derivatives were tested for their anti-inflammatory activities, COX-1 
and COX-2 inhibitory activities, ulcerogenic effects and acute toxicity [7]. The usual synthesis of pyrazole ring 
system has been executed in the literature via 1,3-dipolar cycloaddition reactions of alkenes and alkynes with nitrile 
imines generated in situ from aldehyde phenylhydrazones [8]. Chloramine-T was extensively used reagent for in situ 
generation of nitrile imines from aldehyde phenylhydrazones [9].  
 
In search of new antimicrobial and antioxidant agents; the present project of synthesizing novel pyrazoles and study 
their biological properties was undertaken. We herein report the synthesis of series of isomeric pyrazoles (3, 4); 
which involve 1,3-dipoar cycloaddition reaction of benzalacetone (1) and nitrile imines generated in situ from 
aldehyde phenylhydrazones (2) using chloramine-T (CAT) as catalytic dehydrogenating agent; and the antimicrobial 
and antioxidant activities of the major products (3).  
 
EXPERIMENTAL SECTION 
 
IR spectra were recorded on Shimadzu 8300 spectrometer. The 1H NMR and 13C NMR spectra were recorded on a 
Bruker supercon 400 MHz spectrophotometer using CDCl3 as solvent and TMS as an internal standard. The 
Chemical shifts are expressed in δ ppm. Mass spectra were obtained on Shimadzu LCMS-2010A spectrophotometer 
K. Ajay Kumar et al                 J. Chem. Pharm. Res., 2015, 7(4):854-859 
______________________________________________________________________________ 
855 
(chemical ionization) and the relative intensities of the important fragments were given in the parenthesis. Elemental 
analysis was obtained on a Thermo Finnigan Flash EA 1112 CHN analyser. Chromatographic separations were 
carried out on silica gel (70-230 mesh, Merck) column using hexane: ethyl acetate (8:2) as eluent.  
 
In a typical 1,3-dipolar cycloaddition reaction, the nitrile imines generated by the catalytic dehydrogenation of 
aromatic aldehyde phenylhydrazones (2) with chloramine-T in ethyl alcohol were trapped in situ with benzalacetone 
(1), the reaction yielded an isomeric mixture of  1-(3-aryl-1,4-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)ethanones (3) 
as major and 1-(1-aryl-3,4-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)ethanones (4) as minor products (Scheme-1). 
 
 
 
General procedure for the cycloaddition 
A mixture of aldehyde phenylhydrazone (2) (4.0 mmol), benzalacetone (1) (4.0 mmol) and chloramine-T trihydrate 
(5.0 mmol) in ethanol was refluxed on water bath for 3 hours. The progress of the reaction was monitored by TLC. 
After the completion of the reaction, the sodium chloride formed was filtered off, and the solvent was evaporated in 
vacuo. The residual mass was extracted into ether (25 mL), washed successively with water (2 X 15 mL), 10% 
sodium hydroxide (2 X 15 mL) and saturated brine solution (1 X 10 mL). The organic layer was dried over 
anhydrous sodium sulphate and the solvent was evaporated to dryness. The reaction produced light to brown oily 
mass, which showed two spots corresponding to the cycloadducts (3 and 4) in TLC. The products were separated by 
column chromatography using hexane: ethyl acetate (8:2 v/v) as eluent.  
 
Antibacterial activity 
Minimum inhibitory concentrations (MICs) were determined by broth dilution technique [10]. The nutrient broth, 
which contain logarithmic serially two-fold diluted amount of test compound and controls were inoculated with 
approximately 5 x 105 c.f.u of actively dividing bacteria cells. The bacterial cultures were incubated for 24 hrs at 
37⁰C and fungi cultures were incubated for 72 hrs at 37⁰C, the growth was monitored visually and 
spectrophotometrically. The lowest concentration required to arrest the growth of bacteria and fungi was regarded as 
minimum inhibitory concentration (MIC). The test compounds were screened for their antibacterial activity against 
Gram-negative bacteria species Escherichia coli, Salmonella typhimurium, Gram-positive bacteria species Bacillus 
substilis, Staphylococus aureus. And antifungal activity against Aspergillus niger, Aspergillus flavus, C. albicans, 
Fusarium oxysporium. The antibiotics streptomycin and nystatin were used as standard drugs against bacteria and 
fungi species respectively. The experiments were carried out in triplicate; the results were taken as a mean of three 
determinations. 
 
Antioxidant activity  
The capacity to scavenge the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) was monitored according to 
the Blois method [11] using ascorbic acid as standard antioxidant. Samples dissolved in methanol (0-50 µg/mL; 0-5 
µg/mL ascorbic acid) in 200 µL aliquot was mixed with 100 mM tris-HCl buffer (800 µL, pH 7.4) and then added 1 
mL of 500 µM DPPH in ethanol (final concentration of 250 µM). The mixture was shaken vigorously and left to 
stand for 20 min at room temperature in the dark. The absorbance of the resulting solution was measured 
spectrophotometrically at 517 nm. The experiments were performed in triplicates; the results are expressed as mean 
± standard deviation (SD). 
 
RESULTS AND DISCUSSION 
 
1-(3-(4-Fluorophenyl)-1,4-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)ethanone, 3a: Obtained as a light brown oil in 
64% yield. IR (nujol): 1678, 1750 cm-1. 1H NMR (CDCl3):  2.356 (s, 3H, CH3), 4.122 (d, 1H, J= 8.6Hz, C4-H), 
4.390 (d, 1H, J= 9.8Hz, C5-H), 6.708 (t, 1H, Ph-H), 7.222-7.561 (m, 9H, C6H5, Ph-H), 7.724 (dd, 2H, Ar-H), 7.812 
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(dd, 2H, Ar-H). 13C NMR (CDCl3):  26.30 (1C, CH3), 42.22 (1C, 4-C), 66.98 (1C, 5-C), 121.56 (2C, Ph-C), 122.31 
(2C, Ar-C), 124.77 (1C, Ph-C), 127.26 (1C, Ar-C), 128.66 (2C, Ar-C), 129.12 (1C, C6H5-C), 129.72 (2C, C6H5-C), 
130.13 (1C, C6H5-C), 131.44 (2C, Ph-C), 135.09 (1C, Ph-C), 138.00 (1C, 3-C), 141.03 (1C, C6H5-C), 149.92 (1C, 
Ar-C),170.06 (1C, C=O). MS (relative abundance) m/z: 359 (MH+, 29), 358 (M+, 100), 315 (32), 302 (12), 235 (23), 
213 (11), 198 (44), 137 (25).  Anal. Cacld. for C23H19FN2O: C, 77.08, H, 5.34, N, 7.82%; Found: C, 77.02, H, 5.37, 
N, 7.85%.  
 
1-(3-(4-Chlorophenyl)-1,4-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)ethanone, 3b: Obtained as a light brown oil in 
78% yield. IR (nujol): 1688, 1744 cm-1. 1H NMR (CDCl3):  2.372 (s, 3H, CH3), 4.260 (d, 1H, J= 8.0Hz, C4-H), 
4.373 (d, 1H, J= 7.6Hz, C5-H), 6.604 (t, 1H, Ph-H), 7.203-7.559 (m, 9H, C6H5, Ph-H), 7.703 (dd, 2H, Ar-H), 7.808 
(dd, 2H, Ar-H). MS (relative abundance) m/z: 376 (MH+, 37Cl, 33), 374 (MH+, 35Cl, 28), 373 (M+, 35Cl, 100), 331 
(08), 269 (06), 235 (08). Anal. Cacld. for C23H19ClN2O: C, 73.69, H, 5.11, N, 7.47%; Found: C, 73.71, H, 5.14, N, 
7.56%.  
 
1-(1,4-Diphenyl-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-5-yl)ethanone, 3c: Obtained as a light brown oil in 
80% yield. IR (nujol): 1680, 1740 cm-1. 1H NMR (CDCl3): 2.125 (s, 3H, CH3), 2.325 (s, 3H, CH3), 4.222 (d, 1H, J= 
9.2Hz, C4-H), 4.430 (d, 1H, J= 8.1Hz, C5-H), 6.728 (t, 1H, Ph-H), 7.236-7.568 (m, 9H, C6H5, Ph-H), 7.719 (dd, 2H, 
Ar-H), 7.892 (dd, 2H, Ar-H). 13C NMR (CDCl3): 21.80 (1C, CH3), 26.54 (1C, CH3), 43.02 (1C, 4-C), 67.08 (1C, 5-
C), 121.42 (2C, Ph-C), 122.55 (2C, Ar-C), 124.21 (1C, Ph-C), 127.30 (1C, Ar-C), 128.28 (2C, Ar-C), 129.20 (1C, 
C6H5-C), 129.88 (2C, C6H5-C), 130.24 (1C, C6H5-C), 131.10 (2C, Ph-C), 135.02 (1C, Ph-C), 137.78 (1C, 3-C), 
141.32 (1C, C6H5-C), 149.82 (1C, Ar-C), 170.01 (1C, C=O). Anal. Cacld. for C24H22N2O: C, 81.33, H, 6.26, N, 
7.90%; Found: C, 81.31, H, 6.20, N, 7.80%.  
 
1-(1,3,4-Triphenyl-4,5-dihydro-1H-pyrazol-5-yl)ethanone, 3d: Obtained as a light brown oil in 72% yield. IR 
(nujol): 1695, 1735 cm-1. 1H NMR (CDCl3):  2.225 (s, 3H, CH3), 4.214 (d, 1H, J= 8.0Hz, C4-H), 4.446 (d, 1H, J= 
6.8Hz, C5-H), 6.733 (t, 1H, Ph-H), 7.216-7.571 (m, 14H, C6H5, Ph-H). MS (relative abundance) m/z: 341 (MH+, 26), 
340 (M+, 100), 297 (14), 235 (30), 195 (22), 180 (14), 119 (30). Anal. Cacld. for C23H20N2O: C, 81.15, H, 5.92, N, 
8.23%; Found: C, 81.07, H, 5.90, N, 8.18%.  
 
1-(3-(4-Methoxyphenyl)-1,4-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)ethanone, 3e: Obtained as light brown oil in 
68% yield. IR (nujol): 1690, 1742 cm-1.    1H NMR (CDCl3):  2.205 (s, 3H, CH3), 3.900 (s, 3H, OCH3), 4.208 (d, 1H, 
J= 8.0Hz, C4-H), 4.442 (d, 1H, J= 7.8Hz, C5-H), 6.732 (t, 1H, Ph-H), 7.240-7.663 (m, 9H, C6H5, Ph-H), 7.701 (dd, 
2H, Ar-H), 7.992 (dd, 2H, Ar-H). 13C NMR (CDCl3):  26.26 (1C, CH3), 42.32 (1C, 4-C), 55.64 (1C, OCH3), 66.14 
(1C, 5-C), 121.18 (2C, Ph-C), 122.54 (2C, Ar-C), 124.85 (1C, Ph-C), 127.17 (1C, Ar-C), 128.32 (2C, Ar-C), 129.30 
(1C, C6H5-C), 129.84 (2C, C6H5-C), 130.10 (1C, C6H5-C), 131.36 (2C, Ph-C), 134.98 (1C, Ph-C), 137.44 (1C, 3-C), 
140.94 (1C, C6H5-C), 149.33 (1C, Ar-C), 169.86 (1C, C=O). MS (relative abundance) m/z: 371 (MH+, 18), 370 (M+, 
100), 327 (28), 314 (10), 265 (08), 235 (24), 225 (15), 210 (16), 149 (32). Anal. Cacld. for C24H22N2O2: C, 77.81, H, 
5.99, N, 7.56%; Found: C, 77.74, H, 5.93, N, 7.50%.  
 
1-(3-(3,4-Dimethoxyphenyl)-1,4-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)ethanone, 3f: Obtained as a light brown oil 
in 75% yield. IR (nujol): 1688, 1755 cm-1. 1H NMR (CDCl3):  2.250 (s, 3H, CH3), 3.896 (s, 6H, OCH3), 4.382 (d, 
1H, J= 8.1Hz, C4-H), 4.769 (d, 1H, J= 8.8Hz, C5-H), 6.721 (t, 1H, Ph-H), 6.911 (d, 1H, Ar-H), 7.240-7.600 (m, 
11H, C6H5, Ph-H). 13C NMR (CDCl3):  26.28 (1C, CH3), 42.48 (1C, 4-C), 55.60 (2C, OCH3), 66.29 (1C, 5-C), 
121.02 (2C, Ph-C), 123.76 (1C, Ar-C), 124.50 (1C, Ar-C), 125.15 (1C, Ph-C), 127.67 (1C, Ar-C), 128.56 (1C, Ar-
C), 129.22 (1C, C6H5-C), 129.44 (2C, C6H5-C), 130.02 (2C, C6H5-C), 131.57 (2C, Ph-C), 134.75 (1C, Ph-C), 136.30 
(1C, 3-C), 139.77 (1C, C6H5-C), 149.23 (2C, Ar-C), 169.22 (1C, C=O). MS (relative abundance) m/z: 401 (MH+, 
17), 357 (17), 346 (M-56, 100), 331 (58), 255 (16), 240 (14), 235 (24), 179 (12). Anal. Cacld. for C25H24N2O3: C, 
74.98, H, 6.04, N, 7.00%; Found: C, 75.12, H, 5.91, N, 7.06%.  
 
1-(3-(Furan-2-yl)-1,4-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)ethanone, 3g: Obtained as a light brown oil in 76% 
yield. IR (nujol): 1684, 1745 cm-1. 1H NMR (CDCl3):  2.212 (s, 3H, CH3), 4.211 (d, 1H, J= 8.3Hz, C4-H), 4.439 (d, 
1H, J= 9.9Hz, C5-H), 6.532 (d, 1H, Ar-H), 6.712 (t, 1H, Ph-H), 6. 912 (d, 1H, Ar-H), 7.258-7.610 (m, 10H, C6H5, 
Ph-H). Anal. Cacld. for C21H18N2O2: C, 76.34, H, 5.49, N, 8.48%; Found: C, 76.26, H, 5.52, N, 8.45%.  
 
The physical and analytical data of the two isomeric minor products 4a and 4c were given below. 
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1-(1-(4-Fluorophenyl)-3,4-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)ethanone, 4a: Obtained as a light brown oil in 
64% yield. IR (nujol): 1678, 1750 cm-1. 1H NMR (CDCl3):  2.356 (s, 3H, CH3), 4.122 (d, 1H, J= 8.6Hz, C4-H), 
4.390 (d, 1H, J= 9.8Hz, C5-H), 6.708 (t, 1H, Ph-H), 7.222-7.561 (m, 9H, C6H5, Ph-H), 7.724 (dd, 2H, Ar-H), 7.812 
(dd, 2H, Ar-H). 13C NMR (CDCl3):  26.30 (1C, CH3), 42.22 (1C, 4-C), 66.98 (1C, 5-C), 121.56 (2C, Ph-C), 122.31 
(2C, Ar-C), 124.77 (1C, Ph-C), 127.26 (1C, Ar-C), 128.66 (2C, Ar-C), 129.12 (1C, C6H5-C), 129.72 (2C, C6H5-C), 
130.13 (1C, C6H5-C), 131.44 (2C, Ph-C), 135.09 (1C, Ph-C), 138.00 (1C, 3-C), 141.03 (1C, C6H5-C), 149.92 (1C, 
Ar-C),170.06 (1C, C=O). MS (relative abundance) m/z: 359 (MH+, 29), 358 (M+, 100), 315 (32), 302 (12), 235 (23), 
213 (11), 198 (44), 137 (25).  Anal. Cacld. for C23H19FN2O: C, 77.08, H, 5.34, N, 7.82%; Found: C, 77.02, H, 5.37, 
N, 7.85%. 
 
1-(3,4-Diphenyl-1-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-5-yl)ethanone, 4c: Obtained as a light brown oil in 
80% yield. IR (nujol): 1680, 1740 cm-1. 1H NMR (CDCl3): 2.125 (s, 3H, CH3), 2.325 (s, 3H, CH3), 4.222 (d, 1H, J= 
9.2Hz, C4-H), 4.430 (d, 1H, J= 8.1Hz, C5-H), 6.728 (t, 1H, Ph-H), 7.236-7.568 (m, 9H, C6H5, Ph-H), 7.719 (dd, 2H, 
Ar-H), 7.892 (dd, 2H, Ar-H). 13C NMR (CDCl3): 21.80 (1C, CH3), 26.54 (1C, CH3), 43.02 (1C, 4-C), 67.08 (1C, 5-
C), 121.42 (2C, Ph-C), 122.55 (2C, Ar-C), 124.21 (1C, Ph-C), 127.30 (1C, Ar-C), 128.28 (2C, Ar-C), 129.20 (1C, 
C6H5-C), 129.88 (2C, C6H5-C), 130.24 (1C, C6H5-C), 131.10 (2C, Ph-C), 135.02 (1C, Ph-C), 137.78 (1C, 3-C), 
141.32 (1C, C6H5-C), 149.82 (1C, Ar-C), 170.01 (1C, C=O). Anal. Cacld. for C24H22N2O: C, 81.33, H, 6.26, N, 
7.90%; Found: C, 81.31, H, 6.20, N, 7.80%. 
 
The structures of the cycloadducts were provided by IR, 1H NMR, 13C NMR, MS studies and elemental analysis. 
For instance, in IR spectra, the cycloadducts 3a-g gave the absorptions bands in the region 1735-1755 cm-1 for C=N 
(str) group of newly formed five membered ring, a strong absorption bands in the region 1678-1695 cm-1 for C=O 
(str).  In 1H NMR spectra, the cycloadducts showed the peaks due to aromatic and substituent protons at the 
expected region. The consistent pattern signals due to C4-H and C5-H appeared as doublet in the region δ 4.122-
4.382 ppm., and δ 4.373-4.769 ppm. The coupling constant (J) values obtained were in range 6.8-9.9 Hz; indicating 
that both C4- and C5- protons are cis in the products. 
 
In 13C NMR, all products gave the signals due to aromatic and substituent carbons at the expected region. The 
consistent pattern signals observed for the carbon atom of the newly formed five membered rings. The signals 
appeared in the region δc 42.22-43.02 ppm, δc 66.14-67.08 ppm, and δc 136.30-138.00 ppm. for C4-carbon, C5-
carbon, and  C3-carbon respectively supported the formation of cycloadducts. The cycloadducts 3a-g gave 
significantly stable molecular ion peaks with a relative abundance ranging up to 40% and base peak at (MH+). 
Further, all showed satisfactorily CHN analysis with a deviation of ±0.02% from the theoretically calculated values. 
All these observations strongly favor the formation of the cycloadducts. 
 
The results of MICs) of the synthesized compounds 3a-g against different bacterium were tabulated in table-1. 
 
Table 1: MIC’s of the synthesized compounds 3a-g against bacteria species 
 
Compound Minimum inhibitory concentration (MIC’s) in µg/mL* 
 S. aureus S. pyogenes S. typhimurium E. coli 
3a 50 100 100 50 
3b 100 200 50 25 
3c 50 50 100 200 
3d 50 100 ** ** 
3e 25 50 200 100 
3f 25 25 100 100 
3g 50 100 ** ** 
streptomycin 25 50 50 25 
* Values are expressed as mean of the three determinations (n=3). 
** No inhibition even at a higher concentration of 200 µg/mL. 
 
The synthesized compounds exerted a wide range of in vitro antibacterial activity against the tested organisms. 
However, the compound 3g failed to inhibit the growth against S. typhimurium and E.coli organisms tested and 
compound 3d failed to show the inhibition against S. Typhimurium and E. coli organisms even at a higher 
concentration of 200 µg/mL. The compound 3f having two electron donating methoxy substituents good activity 
particularly against S. aureus and S. Pyogenes with reference to the standard. The compound 3b having chloro 
substitution exhibited good activity against S. typhimurium and E. coli species with reference to the standard. 
K. Ajay Kumar et al                 J. Chem. Pharm. Res., 2015, 7(4):854-859 
______________________________________________________________________________ 
858 
The results of MICs) of the synthesized compounds 3a-g against different fungi species were tabulated in table-2. 
 
Table 2: MIC’s of the synthesized compounds 3a-g against fungi species 
 
Compound Minimum inhibitory concentration (MIC’s) in µg/mL* 
 A. niger A. flavus C. albicans F. oxysporium 
3a 50 100 100 50 
3b 25 50 25 25 
3c 50 50 100 200 
3d 50 100 100 50 
3e 25 50 50 50 
3f 100 200 200 100 
3g ** ** ** ** 
nystatin 25 50 50 25 
* Values are expressed as mean of the three determinations (n=3). 
** No inhibition even at a higher concentration of 200 µg/mL. 
 
The synthesized compounds showed promising in vitro antifungal activity against the tested organisms. The 
compound 3b having chloro and 3e having methoxy substitution in the aromatic ring exerted remarkable activity 
against all the tested organicsm. The compounds 3a, 3c, 3d and 3f showed moderate to good inhibition. But the 
compound 3g failed to inhibit the growth all the tested organisms.  
 
The results of antioxidant activity of the synthesized compounds against different bacterium were tabulated in table-
3. 
 
Table-3: DPPH Radical Scavenging activity of the compounds 3a-g relative  to the standard ascorbic acid 
 
Samples % Radical Scavenging activity  
Concentration (µg/mL) 
10 20 30 40 50 
3a 14.46 ± 0.82 20.30 ± 0.89 28.81 ± 1.01 37.52 ± 0.98 40.73 ± 1.00 
3b 13.12 ± 0.78 16.36 ± 0.92 24.42 ± 0.83 27.23 ± 0.78 31.92 ± 1.00 
3c 9.22 ± 0.85 11.96 ± 0.89 22.61 ± 0.68 28.96 ± 0.98 32.67 ± 0.71 
3d 22.76 ± 0.94 24.23 ± 0.88 36.90 ± 0.74 48.66 ± 0.98 59.17 ± 0.82 
3e 13.16 ± 0.80 18.22 ± 1.00 29.90 ± 0.94 32.61 ± 0.95 36.18 ± 0.80 
3f 18.32 ± 0.86 25.22 ± 0.76 30.26 ± 1.00 32.22 ± 0.90 37.96 ± 0.88 
3g 11.12 ± 0.88 14.36 ± 0.98 19.80 ± 0.81 24.75 ± 0.78 26.80 ± 1.00 
Control at Concentration 0 µg/mL 0.00 ± 0.00 
*Values are expressed as mean ± standard deviation (n=3) 
 
The compounds 3a-g showed promising free radical scavenging ability but of lesser activity compared with the 
standard antioxidant. No much significant variations in the free radical scavenging ability were observed at the 
initial concentrations of (10-20 µg/mL). However, at the higher concentrations (30-50 µg/mL) all showed a 
promising activity. Among the series of synthesized compounds 3d showed radical scavenging ability up to 60%, 
where as 3a, 3b, 3c, 3e and 3f showed radical scavenging ability up to 36-40% with reference to the standard 
antioxidant. The compound 3g showed poorer antioxidant activity. 
 
CONCLUSION 
 
The divergence in the biological activity of synthesized new compounds by a simple 1,3-dipolar cycloaddition 
reactions validates the significance of this study. The study revealed that the most of the compounds tested showed 
moderate to good antimicrobial and antioxidant activities. However, the effect of compounds on the host cell and 
their mode of action remain to be studied. 
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